Patent Application
20240065750
Discogenic back pain is a troublesome disorder of the spinal column, where one or more intervertebral discs are the source of pain. It is estimated that one out of every three patients with chronic low back pain have discogenic back pain and that about five percent of the adult population suffers from this disorder.
The spinal column is made up of a series of interlocking bones called vertebrae that are separated by intervertebral discs. The spine provides load-bearing support for one-half of the body's mass and it protects the nerves of the spinal column. Intervertebral discs contain two parts; an annulus fibrosus which is an outer ring-like structure and a nucleus pulposus which is the gel-like interior of the disc void of nerves. However, the outer third of the annulus fibrosus contains nerve fibers. The intervertebral discs provide shock absorption and facilitate the bending of the spine. The combination of the vertebrae and intervertebral discs at each vertebral segment allows for motion of the spine, in particular, flexing, rotation, and extension. The motion and support functions of the spine, in combination with the many interlocking parts and nerves associated with the spinal column, can result in back pain, such as discogenic back pain due to various reasons.
Discogenic back pain can include bulging, herniated, or ruptured discs which can trigger a response from adjacent nerves, causing the pain sensation. Even after a herniated disc heals, the anatomy of the disc may not return to normal and may continue to cause pain. Even in the case where a disc is not herniated, chronic pain may present itself as people age because the annulus fibrosus begins to decay and the resulting small tears in the wall are infiltrated by nerves and blood vessels, causing pressure and chronic pain.
One common way to diagnose a patient with discogenic back pain is through the use of a diagnostic procedure known as discography. During this procedure, selected intervertebral discs are pressurized with an injected sterile liquid to induce pain in the affected intervertebral discs. However, this procedure involves full-thickness penetration of the annulus and injection of contrast media, making the procedure somewhat invasive which can increase the risk of disc degeneration.
Once a disc or discs in pain are diagnosed, the disc or discs can be treated through various surgical or non-surgical methods. However, there is a need for devices and methods that both diagnose and treat discogenic back pain that are less invasive than the standard procedures currently available.
Devices and methods are provided that allow for a less invasive option in diagnosing and treating discogenic back pain. In various embodiments a device is provided for supplying electrical current to an intervertebral disc. The device comprises a cannula having a proximal end and a distal end and a longitudinal axis therebetween. The distal end comprises a beveled tip for contacting a region of the intervertebral disc, and an electrode disposed within or on a surface of the cannula adjacent to the distal end. The electrode is configured to discharge electrical current to the region of the intervertebral disc.
In some embodiments, a method of diagnosing discogenic back pain is provided. The method comprises administering electrical current from a device to a region of the intervertebral disc, the device comprising a cannula having a proximal end and a distal end and a longitudinal axis therebetween, the distal end comprising a beveled tip for contacting a region of the intervertebral disc, an electrode disposed within or on a surface of the cannula adjacent to the distal end, the electrode configured to discharge electrical current to the region of the intervertebral disc.
In some embodiments, a method of diagnosing and treating discogenic back pain is provided. The method comprises administering electrical current from a device to a region of the intervertebral disc, the device comprising a cannula having a proximal end and a distal end and a longitudinal axis therebetween, the distal end comprising a beveled tip for contacting a region of the intervertebral disc, an electrode disposed within or on a surface of the cannula adjacent to the distal end, the electrode configured to discharge electrical current to the region of the intervertebral disc to evoke a pain response; and administering an effective amount of a neurotoxin to the intervertebral disc to reduce the back pain.
Additional features and advantages of various embodiments will be set forth in part in the description that follows, and in part will be apparent from the description, or may be learned by practice of various embodiments. The objectives and other advantages of various embodiments will be realized and attained by means of the elements and combinations particularly pointed out in the description and appended claims.
In part, other aspects, features, benefits and advantages of the embodiments will be apparent with regard to the following description, appended claims and accompanying drawings where:
It is to be understood that the figures are not drawn to scale. Further, the relation between objects in a figure may not be to scale, and may in fact have a reverse relationship as to size. The figures are intended to bring understanding and clarity to the structure of each object shown, and thus, some features may be exaggerated in order to illustrate a specific feature of a structure.
Devices and methods are provided that allow for a less invasive option in diagnosing and treating discogenic back pain. The following description is presented to enable any person skilled in the art to make and use the present disclosure. Descriptions of specific embodiments and applications are provided only as examples and various modifications will be readily apparent to those skilled in the art.
The present disclosure may be understood more readily by reference to the following detailed description of the disclosure presented in connection with the accompanying drawings, which together form a part of this disclosure. It is to be understood that this disclosure is not limited to the specific devices, methods, conditions or parameters described and/or shown herein, and that the terminology used herein is for the purpose of describing particular embodiments by way of example only and is not intended to be limiting of the claimed disclosure.
As used in the specification and including the appended claims, the singular forms “a,” “an,” and “the” include the plural, and reference to a particular numerical value includes at least that particular value, unless the context clearly dictates otherwise.
Ranges may be expressed herein as from “about” or “approximately” one particular value and/or to “about” or “approximately” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value.
Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It is also understood that all spatial references, such as, for example, horizontal, vertical, top, upper, lower, bottom, left and right, are for illustrative purposes only and can be varied within the scope of the disclosure.
For purposes of the description contained herein, with respect to components and movement of components described herein, “forward” or “distal” (and forms thereof) means forward, toward or in the direction of the forward, distal end of the device and/or cannula portion of the device that is described herein, and “rearward” or “proximal” (and forms thereof) means rearward or away from the direction of the forward, distal end of the device and/or cannula portion of the device that is described herein. However, it should be understood that these uses of these terms are for purposes of reference and orientation with respect to the description and drawings herein, and are not intended to limit the scope of the claims.
Spatially relative terms such as “under,” “below,” “lower,” “over,” “upper,” and the like, are used for ease of description to explain the positioning of one element relative to a second element. These terms are intended to encompass different orientations of the device in addition to different orientations than those depicted in the figures. Further, terms such as “first”, “second”, and the like, are also used to describe various elements, regions, sections, etc., and are also not intended to be limiting. Like terms refer to like elements throughout the description.
As used herein, the terms “having,” “containing,” “including,” “comprising,” and the like are open ended terms that indicate the presence of stated elements or features, but do not preclude additional elements or features.
The term “discogenic back pain” refers to a disorder where one or more intervertebral discs are the source of pain. Discogenic back pain can include bulging, herniated, or ruptured discs which can trigger a response from proximate nerves, causing a pain sensation.
The headings below are not meant to limit the disclosure in any way; embodiments under any one heading may be used in conjunction with embodiments under any other heading.
Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying drawings. While the invention will be described in conjunction with the illustrated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents that may be included within the invention as defined by the appended claims.
As shown in
The device comprises a cannula 12 having a proximal end 14, a distal end 16 and a longitudinal axis XX disposed therebetween. The cannula is designed to cause minimal physical trauma to the disc of a patient. The cannula may alternatively be a needle. In some embodiments, a stylet may close the lumen of the needle during placement, running the length of longitudinal axis XX, with removal prior to administering a therapeutic substance.
The distal end of the cannula comprises a beveled tip 18, as shown in
An electrode 26 is disposed within or on a surface 22 of the cannula adjacent to the distal end. In some embodiments, the electrode can be a wire that runs along the needle or cannula, such that the tip of the electrode is near the top of the needle. It is from the tip that current travels into tissue.
The electrode is configured to discharge electrical current to a region of the intervertebral disc to determine whether a disc is in pain. In some embodiments, a unipolar electrode can be used that has a grounding pad placed on the patient's body. For example, when a disc is the cause of pain in a patient, the electrical current discharged will create a positive pain response in the patient. In some embodiments, more than one electrode can be disposed within or on the surface of the cannula. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 electrodes can be disposed within or on the surface of the cannula. Electrodes may be arranged in a bipolar arrangement, with the distal end of a return electrode approximately 0.1-10 mm proximal to the active electrode.
In some embodiments, the active electrode discharges from about 0.5 to about 50 mAMP pulses of current, or from about 2 to about 20 mAMP pulses of current. In some embodiments, the electrode discharges from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 to about 50 mAMP pulses of current.
In some embodiments, the electrical current is administered to a region of the intervertebral disc in pulses. In some embodiments, the electrical current is administered over a period of time, such as, for example, from about 1 to about 10 seconds. In some embodiments, the electrical current is administered over a period of 1, 2, 3, 4, 5, 6, 7, 8, 9 to about 10 seconds.
The proximal end is configured to be coupled to an electrical generator 24 by electrode 26, as shown in
In some embodiments, the proximal end of the cannula comprises a port 28 for engagement with a syringe 30 having a plunger 32. The port and syringe engagement facilitates administration of a local anesthetic, anti-inflammatory and/or a neurotoxin through a channel 42 within the cannula to treat an intervertebral disc that tested positive for pain during discharge of an electrical current from the device to the selected intervertebral disc.
The port is in alignment with longitudinal axis XX. Alternatively, in some embodiments, the port can be angled relative to longitudinal axis XX and can be positioned at an angle that is 5 to about 90 degrees relative to longitudinal axis XX. In some embodiments, the angle can be from about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 to about 90 degrees relative to longitudinal axis XX.
In some embodiments, a proximal end 34 of the port includes an interior surface that defines threading 36 that is configured for engagement with threading 40 on an end 38 of the syringe. In some embodiments, the end of the syringe can be a luer lock fitting.
The syringe is configured for administration of a local anesthetic, an anti-inflammatory and/or a neurotoxin. In some embodiments, the local anesthetic is lidocaine, clonidine, bupivacaine, ropivacaine, mepivacaine, etidocaine, levobupivacaine, trimecaine, carticaine, articaine or a combination thereof. Alternatively, opioid analgesics can be administered such as buprenorphine, butorphanol, dextromoramide, dezocine, dextropropoxyphene, diamorphine, fentanyl, alfentanil, sufentanil, hydrocodone, hydromorphone, ketobemidone, levomethadyl, levorphanol, mepiridine, methadone, morphine, nalbuphine, opium, oxycodone, papaveretum, pentazocine, pethidine, phenoperidine, piritramide, dextropropoxyphene, remifentanil, sufentanil, tilidine, tramadol, codeine, dihydrocodeine, meptazinol, dezocine, eptazocine, flupirtine or a combination thereof.
In some embodiments, the anti-inflammatory includes, but is not limited to a statin, sulindac, sulfasalazine, naroxyn, diclofenac, indomethacin, ibuprofen, flurbiprofen, ketoprofen, aclofenac, aloxiprin, aproxen, aspirin, diflunisal, fenoprofen, mefenamic acid, naproxen, phenylbutazone, piroxicam, meloxicam, salicylamide, salicylic acid, desoxysulindac, tenoxicam, ketoralac, clonidine, flufenisal, salsalate, triethanolamine salicylate, aminopyrine, antipyrine, oxyphenbutazone, apazone, cintazone, flufenamic acid, clonixeril, clonixin, meclofenamic acid, flunixin, colchicine, demecolcine, allopurinol, oxypurinol, benzydamine hydrochloride, dimefadane, indoxole, intrazole, mimbane hydrochloride, paranylene hydrochloride, tetrydamine, benzindopyrine hydrochloride, fluprofen, ibufenac, naproxol, fenbufen, cinchophen, diflumidone sodium, fenamole, flutiazin, metazamide, letimide hydrochloride, nexeridine hydrochloride, octazamide, molinazole, neocinchophen, nimazole, proxazole citrate, tesicam, tesimide, tolmetin, triflumidate, fenamates (mefenamic acid, meclofenamic acid), nabumetone, celecoxib, etodolac, nimesulide, apazone, gold, tepoxalin; dithiocarbamate, or a combination thereof. Anti-inflammatory agents can also include other compounds such as steroids, such as for example, fluocinolone, cortisol, cortisone, hydrocortisone, fludrocortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, dexamethasone, beclomethasone, fluticasone interleukin-1 receptor antagonists, thalidomide (a TNF-α release inhibitor), thalidomide analogues (which reduce TNF-α production by macrophages), bone morphogenetic protein (BMP) type 2 or BMP-4 (inhibitors of caspase 8, a TNF-α activator), quinapril (an inhibitor of angiotensin II, which upregulates TNF-α), interferons such as IL-11 (which modulate TNF-α receptor expression), and aurin-tricarboxylic acid (which inhibits TNF-α), guanidinoethyldisulfide, or a combination thereof.
In some embodiments, the neurotoxin can include, but is not limited to inhibitors of sodium channels, neurotoxins targeting transient receptor potential cation channel subfamily V member 1 (TRPV1), botulinum toxins or a combination thereof. In particular, inhibitors of sodium channels include, but are not limited to, saxitoxin, μ-conotoxin, tetrodotoxin, batrachotoxin, grayanotoxin, α-scorpion toxins (e.g., bukatoxin), β-scorpion toxins, and brevetoxin. In some embodiments, tarantula toxins with relative selectivity for sodium channels specific to pain fibers may be used for selective silencing of nociception in the disc. In some embodiments, this includes Δ-theraphotoxin-Hm1a and Δ-theraphotoxin-Hm1b.
In some embodiments, the neurotoxins targeting TRPV1 include, but are not limited to, capsaicin and its analogues (homocapsaicin, homodihydrocapsaicin, nonivamide, nordihydrocapsaicin, dihydrocapsaicin), resinferatoxin or a combination thereof.
In some embodiments, alternative strategies for targeting NAV1.7 and/or TRPV1 may include administration of monoclonal antibodies for one or both of these pain fiber cation channels. In some embodiments, botulinum toxins can be administered including, but not limited to both botulinum toxin A and botulinum toxin B. In the case of botulinum toxins, analgesia may be inhibited by a suppression in Nav1.7 channel expression. Inhibition of acetylcholine neurotransmitter release is not relevant to this indication.
In some embodiments, the neurotoxin is administered in an amount of 1 to about 100 μM to the selected area of the disc. In some embodiments, the neurotoxin is administered in an amount of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 to about 100 μM.
In some embodiments, inhibitors of sodium channels may be administered in a range from about 1 to 100 μM in the maximum recommended injection volume of 500 μL per disc. In some embodiments, when bukatoxin is administered, up to 0.72 mg/mL or up to 0.36 mg delivered in microinjections totaling 500 μL can be administered. In some embodiments, individual microinjections can range from about 10 to about 100 μL as the tip of the device is moved to different regions of the annulus to ensure adequate exposure of all sensitized nerve endings in a disc that tests positive for pain.
In some embodiments, for TRPV1 agonists such as capsaicin, microinjections may contain from 0.1 to 10% of active. In some embodiments, the maximum recommended injection volume is 500 μL (which may be divided into multiple microinjections from 10 to 100 μL) which is equivalent to a dose range of 0.5 to 50 mg.
In some embodiments, for botulinum toxins A and B, a total intra-annular dose of 50 to about 500 IU, or approximately 0.5 to 5.0 ng of protein, can be administered. In some embodiments, administration of the sodium channel inhibitors and TRPV1 agonists will not exceed 500 μL in a total injection volume.
In some embodiments, monoclonal antibodies can be administered in an amount of about 1 to about 100 nM. In some embodiments, to compensate for dilution upon administration of a solution of IgG antibodies to NaV1.7 or TRPV1, the injectate may be at a concentration of 1 to 100 μM. For the typical IgG monoclonal antibody, this will be approximately 150 ng/mL to 15 μg/mL. In some embodiments, the maximum volume administered to the annulus fibrosus is 500 L per disc, which may be divided into multiple microinjections in different areas of the annulus fibrosus.
In some embodiments, the large peptide structure of most of the neurotoxins described above are expected to facilitate containment within the targeted disc upon microinjection of solution or small particle suspensions. This, in turn, mitigates the risk of off target effects following migration to adjacent neurological structures or systemic absorption and distribution.
In some embodiments, the neurotoxins or monoclonal antibodies can be delivered in a semi-solid depot form, and the total dose (mg) may be adjusted up to 10 times higher than the doses described above when delivered as a solution.
In some embodiments, the local anesthetic, an anti-inflammatory and/or a neurotoxin is injected in a liquid carrier such as sterile water, bacteriostatic water for injection (BWFI), a pH buffered solution (e.g. phosphate-buffered saline), sterile saline solution, Ringer's solution or dextrose solution.
In some embodiments, the cannula can include an insulation material 44, as shown in
In some embodiments, the coating or layer of insulation material can have a thickness from about 0.005 to about 4 mm thick. In some embodiments, the thickness can be from about 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3 to about 4 mm thick.
In some embodiments, the cannula can be made from materials, such as for example, polyurethane, polyurea, polyether(amide), PEBA, thermoplastic elastomeric olefin, copolyester, and styrenic thermoplastic elastomer, steel, aluminum, stainless steel, titanium, metal alloys with high non-ferrous metal content and a low relative proportion of iron, carbon fiber, glass fiber, plastics, ceramics or combinations thereof.
In some embodiments, the gauge of the cannula is greater than 21 gauge. In some embodiments, the gauge of the cannula can be in the range of 21-34 gauge. In some embodiments, the cannula can be from about 20 to 150 mm in length. In some embodiments, the tip of the cannula can be tapered.
In some embodiments, the cannula or needle can provide a tactile-type tip, which is flattened or blunt to allow the user to better place the tip at or near the desired target tissue site in the spine.
In various embodiments, the cannula may include a transparent or translucent portion that can be visualizable by ultrasound, fluoroscopy, X-ray, or other imaging techniques. In such embodiments, the transparent or translucent portion may include a radiopaque material or ultrasound responsive topography that increases the contrast of the cannula relative to the absence of the material or topography.
In some embodiments, a lubricant is provided to assist in the insertion of the tip of the cannula into portions of the annulus fibrosis. In some embodiments, the lubricant can be, without limitation, polyethylene glycol (PEG), hyaluronic acid, hyaluronan, lubricin, polyethylene glycol, and any combinations thereof. In some embodiments, salts may be added to the lubricant to increase conductivity and facilitate passage of electrical current to the annular nerve endings. The salts can include calcium chloride, sodium chloride or a combination thereof.
In various embodiments, the tip is configured to match other anatomical tissue shapes to treat other painful conditions. In certain embodiments, the tip may be introduced at a specific depth to locally provide diagnostics and treatment to a portion of the intervertebral disc site while avoiding damage to other areas that are not intended to be diagnosed or treated.
In some embodiments, the cannula includes indicia, for example a depth indicator that may include an analog, such as, for example, a dial with a numerical indicator of angle and/or digital display, such as, for example, LED and/or LCD. The graduations may represent various indicia, such as, for example, numerical, alphabetic and/or specific conditions/orientations, such as, initial depth and/or final depth of penetration into the annulus fibrosus.
In some embodiments, monitoring devices can be coupled to the device comprising sensors that may receive and record data relating to density, impedance, and position of the tip of the cannula in the form of radiowaves, microwaves, spectroscopy, and the like. In different embodiments, sensors comprising a battery, an electrode, a recharger, a transmitter, a receiver, a transceiver, a sensor, a recorder, a capacitor, a transformer, a system control unit, a programmer, an address/positioning unit, a depth sensor, a pressure sensor, a pressure adjuster, a mechanical power generator, a photo/light generator, an ultraviolet light generator, an infrared generator, an optical stimulator, a laser, a radiofrequency generator, a magnetic field generator, a mechanical vibration generator, an ultrasonic wave generator, an electrical field generator, a radiation generator or a fuel cell can be coupled to the device. In some embodiments, the monitoring device may be a recording electrode placed cranial to the target disc, such as in the epidural space or in or near a dorsal root ganglion.
In various aspects, the device can also be coupled to an imaging modality such as ultrasound, CT, fluoroscopy or MRI, overhead 3D stereotactic system (via pre-procedure MRI and/or CT) allowing the user to visualize or otherwise identify the intervertebral disc. For example, imaging devices useful in coupling with the device described herein comprise, without limitation, Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), diffusion MRI (DWI), diffusion tensor MRI (DTI), electroencephalography (EEG), magnetoencephalography (MEG), nuclear neuroimaging, positron emission tomography (PET), single photon emission computed tomography (SPECT), Ictal-Interictal SPECT Analysis by Statistical Parametric Mapping (ISAS), Computed Tomography (CT), x-ray, fluoroscopy, angiography, ultrasonography, transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial electrical stimulation (TES), motor evoked potential (MEP), somatosensory evoked potential (SSEP), phase reversal of somatosensory evoked potential, evoked potential, electrocorticography (ECoG), direct cortical electrical stimulation (DCES), microelectrode recording (MER) or local field potential recording (LFP).
In some embodiments, the device is coupled to software that enables the real time or retrospective review of data coming from different navigation, monitoring and diagnostic tools used during the diagnostic procedure. For example, in various embodiments, the monitoring device can take many different forms. In some implementations, the monitoring device is a dedicated electrical circuit employing various sensors, logic elements, and actuators. In other implementations, the monitoring device is a computer-based system that includes a programmable element, such as a microcontroller or microprocessor, which can execute program instructions stored in a corresponding memory or memories. Such a computer-based system can take many forms, may include many input and output devices, and may be integrated with other system functions, such as the monitoring device, imaging device, a computer network, and other devices that are typically employed during a procedure. For example, a single computer-based system may include a processor that executes instructions to provide the function of the monitoring device; display imaging information associated with a procedure (e.g., from an imaging device); display pressure, temperature, time information and tip position; and serve as an overall interface for the device. In general, various types of monitoring devices are possible and contemplated, and any suitable monitoring device can be employed.
In certain embodiments, the device may include switches for manually controlling the operation of the device by a medical practitioner. The switches can provide functions such as on/off, administering electrical current, and predetermined cycles of administering current by selectively and controllably communicating with the electrical generator.
In some embodiments, the device can be operatively connected to semi-steerable or navigational sources for easier guidance into the intervertebral disc. In various embodiments, the navigational sources can be coupled with a pre-procedure such as, for example, CT, MRI, PET scan, etc. so that the target intervertebral disc can be identified and accurately located during diagnostics and treatment.
In various embodiments, the device may include radiographic markers to help indicate position on imaging procedures (e.g., CT scan, X-ray, fluoroscopy, PET scan, etc.). These may be disposed on or a portion of the device and include, but are not limited to, barium, calcium phosphate, and/or metal beads.
In some embodiments, the device can also be utilized to detect and treat pain from other spinal abnormalities, such as, compression fractures, pars defects, vertebral instability, soft tissue abnormalities in ligaments, tendons, muscles, cartilaginous structures, joints (e.g., facet joints, sacroiliac joints, etc.) or abnormalities resulting from tumors, infection or other infiltrative processes. Pain resulting from nerve root lesions (e.g., compressive lesions from adjacent discs, hypertrophic facet joints, facet joints cysts, faulty hardware positioning, bony foraminal encroachment, spondylolisthesis, spondylolysis, congenitally short pedicles, nerve sheath tumors, granulation tissue and/or arachnoiditis, etc.), spinal nerve compression (e.g., spinal stenosis), peripheral nerve lesions, femoral neuropathy, meralgia paresthetica, peroneal neuropathy, asymmetrical neuropathies, lower limb joint pathology, vascular pathology, degenerative disc and joint disease or the like.
It will be understood that although electrical current electrode 52, the passive electrode 54 and return electrode 56 are shown as separate electrodes, they can be in one cannula or they can be in separate cannulas. It will also be understood that the passive electrode or return electrode, in some embodiments, can receive and conduct electrical current away from the target tissue site (e.g., intervertebral disc), which can then be used by the control circuit to monitor the electrical current delivered to the tissue.
The return electrode, passive electrode and/or electrical current electrode may be of any designs, sizes or shapes. The return electrode, passive electrode and/or electrical current electrode can be integral with the cannula or separated from it.
In some embodiments, the return electrode 56 can receive, conduct and discharge electrical energy at the electrical current electrode 52. In some embodiments, this is accomplished by a switch member that splits the electrical energy or directs the electrical energy to the return electrode.
In some embodiments, an apparatus for providing electrical current treatment comprises a device for providing electrical current treatment and an electrical connection assembly configured to electrically couple the electric current electrode to a power supply 44 that is part of a generator/controller 42 that can convert the energy to the appropriate electrical current, of which further details, in some embodiments, are described in
The present disclosure also provides methods for diagnosing and/or treating discogenic back pain. Examples of discogenic back pain include, but are not limited to bulging, herniated, and/or ruptured discs.
In some embodiments, a method of diagnosing discogenic back pain is provided. The method comprises administering electrical current from a device to a region of the intervertebral disc, the device comprising a cannula having a proximal end and a distal end and a longitudinal axis therebetween, the distal end comprising a beveled tip for contacting a region of the intervertebral disc, an electrode disposed within or on a surface of the cannula adjacent to the distal end, the electrode configured to discharge electrical current to the region of the intervertebral disc. It is to be understood that the device is device 10, as disclosed herein.
In some embodiments, the method further comprises identifying the discogenic back pain by detecting a positive pain response from the patient when the electrical current is administered.
In some embodiments, the method further comprises injecting the selected area of the disc identified with the positive pain response with a local anesthetic and a neurotoxin administered by the needle to treat the selected area of the disc with the positive pain response.
In some embodiments, the proximal end of the device is configured to be coupled to an electrical generator comprising an electrical pulse generator. In some embodiments, the region of the intervertebral disc comprises an annulus fibrosus of the intervertebral disc.
In some embodiments, a method of diagnosing and treating discogenic back pain is provided. The method comprises administering electrical current from a device to a region of the intervertebral disc, the device comprising a cannula having a proximal end and a distal end and a longitudinal axis therebetween, the distal end comprising a beveled tip for contacting a region of the intervertebral disc, an electrode disposed within or on a surface of the cannula adjacent to the distal end, the electrode configured to discharge electrical current to the region of the intervertebral disc to evoke a pain response; and administering an effective amount of a neurotoxin to the intervertebral region to reduce the back pain. It is to be understood that the device is device 10, as disclosed herein.
In some embodiments, the method further comprises positioning a patient such that the patient flexes the spine before the administering electrical current step. In some embodiments, the electrical current is administered to a region of the intervertebral disc comprising a selected area of a healthy first disc of a patient, and the method further comprises recording a first evoked action potential threshold of the first disc of the patient.
In some embodiments, the method further comprises administering electrical current to a selected area of a second disc of the patient with the device; identifying the discogenic back pain by detecting a positive pain response from the patient when the electrical current is administered to the selected area of the second disc; recording a second evoked action potential threshold of the second disc of the patient; and comparing the first evoked action potential threshold with the second evoked action potential threshold to treat the back pain.
In several embodiments, the methods disclosed herein include operatively coupling the device to a source of navigational capability to allow easier insertion and/or pushing through the tissues. In various embodiments, the methods disclosed herein can include a pre-procedure step wherein the deice can be coupled to a CT or MRI machine so that the disc can be identified and accurately located.
In various embodiments, a kit is provided comprising the device. The kit may include additional parts along with the device combined together to be used to diagnose and/or treat discogenic back pain. The kit may include the device in a first compartment. The second compartment may include a vial and/or a syringe for storing a local anesthetic, an anti-inflammatory, a neurotoxin, and/or any instruments needed for the procedure. A third compartment may include gloves, drapes, wound dressings and other procedural supplies for maintaining sterility of the diagnostic and/or treatment site, as well as an instruction booklet, which may include a chart that shows how to implement the device. A fourth compartment may include additional needles and/or sutures. Each tool may be separately packaged in a plastic pouch that is sterilized. A fifth compartment may include an agent for radiographic imaging. A cover of the kit may include illustrations of the diagnostic and/or treatment procedures and a clear plastic cover may be placed over the compartments to maintain sterility.
These and other aspects of the present application will be further appreciated upon consideration of the following Examples, which are intended to illustrate certain particular embodiments of the application but are not intended to limit its scope, as defined by the claims.
Example One: As shown in
Example Two: Sprague Dawley rats were tested for compound action potentials evoked from caudal disc 5 (tail) in the lumbar spinal cord when a current was emitted from device 10 to the site. Following a 10 mAMP pulse of current emitted from the device into the naïve tail disc, a compound evoked potential arrived in the spinal cord with an initial peak corresponding to about 8 meters/second and a secondary peak corresponding to about 5 meters/second nerve conduction velocity (NCV), as shown in
Example Three: A test was performed to evaluate whether positional changes, such as, flexing of the spine during diagnostics for determining discogenic pain would be beneficial. For example, it was postulated that flexing the spine during diagnostics could potentially magnify the difference between a healthy disc and a symptomatic disc with respect to evoked potential threshold when the patient is situated in a non-neutral position.
As shown in
It will be apparent to those skilled in the art that various modifications and variations can be made to various embodiments described herein without departing from the spirit or scope of the teachings herein. Thus, it is intended that various embodiments cover other modifications and variations of various embodiments within the scope of the present teachings.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16257905 | Jan 2019 | US |
| Child | 18502803 | US |
